Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for genetically-defined populations.

For Roche (SIX:ROG; OTCQX:RHHBY), the deal provides a second crack at a precision oncology therapy targeting RET...